Delivery Order SPE2DR25D3101-SPE2DR26F5U71
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,004.40 to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pen injectors, with an ultimate completion date of December 3, 2025. This non-competitive, firm fixed-price delivery order was issued under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. The pharmaceutical will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $2,239.68 to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pen medication, with a completion date of December 11, 2025. This is a firm fixed price, non-set-aside contract to be performed at the contractor's location in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global...
- The Defense Logistics Agency awarded a $2,033.16 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pen/ml on November 6, 2025, with completion scheduled for November 7, 2025. This is a non-set-aside, competitively awarded contract executed under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion vehicle active through December 2026. The delivery order represents a routine pharmaceutical...
- The Defense Logistics Agency awarded a $1,004.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/mL in pre-filled pens, with a completion date of November 25, 2025. This delivery order represents a child contract under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion through December 2026. The award was competitively awarded with no set-aside designation, reflecting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 20, 2025, for the supply of Emgality 120 mg/ml pen, a migraine treatment medication. This firm fixed-price delivery order, valued at $1,034.16, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded a $1,729.00 firm fixed price delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen injectors, with an ultimate completion date of July 25, 2025. This non-set-aside competitive award represents a single delivery order under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. The product will be delivered to the contractor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency has awarded a delivery order valued at $5,723.90 to AmerisourceBergen Drug Corp for the supply of Emgality 120 mg/mL pen/mL, a migraine treatment medication. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The contract carries an ultimate completion date of...
- The Defense Logistics Agency awarded a delivery order valued at $1,401.40 to AmerisourceBergen Drug Corp for Emgality 120 mg/ml pen (injectable migraine treatment) with a completion date of September 17, 2025. This competitively awarded, firm fixed-price delivery order represents a single transaction within AmerisourceBergen's broader pharmaceutical supply relationship with the federal government. The contract specifies performance at the company's Conshohocken, Pennsylvania facility, where...
- The Defense Logistics Agency awarded a delivery order valued at $1,004.40 to AmerisourceBergen Drug Corp for the supply of Emgality 120 mg/ml in pen format. This firm fixed-price delivery order was competitively awarded without set-aside designation and is scheduled for completion by December 9, 2025. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $3,309.37 to AmerisourceBergen Drug Corp for the supply of Emgality 120 mg/ml pen injectors. This firm fixed price, competitively awarded contract was issued on August 5, 2025, with an ultimate completion date of August 6, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- SPE2DR25D3101Indefinite Delivery Contract
- SPE2DR25D3101-SPE2DR26F5U71Delivery Order
The Defense Logistics Agency awarded a $3,348 delivery order to AmerisourceBergen Drug Corp for Emgality 120 mg/mL pen medication, with a completion date of December 23, 2025. This competitive, firm fixed-price contract with no set-aside designation is a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical vendor, serves the Defense Health Agency and other government healthcare systems through its comprehensive DLA prime vendor contract. The SPE2DX vehicle enables the company to supply a broad range of pharmaceutical products, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains to support military healthcare programs globally. This delivery order for Emgality, a calcitonin gene-related peptide antagonist used for migraine treatment, represents one of numerous competitively awarded transactions the company fulfills under this framework agreement.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.3k | 12/21/25 |